Skip to main content

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Completed · Phase 3 · NCT04075825

Conditions: Crohn's Disease, Complex Perianal Fistula

At a glance

Research payments reported, 2025
$55,013
U.S. investigators named
11
Sites paid
11
Planned or actual enrollment
150

About the trial

Sponsor
Takeda
Tested
Placebo (other), Darvadstrocel (biological)
Dates
Started 2019-11-05; completion 2024-04-02
Results posted
Yes

The main aim is to follow-up on long term side effect and symptom improvement of Darvadstrocel in the treatment of complex perianal fistula in adults. Participants will not receive any drug in this study.

From ClinicalTrials.gov, last updated 2025-04-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $55,013 in research payments for this study in 2025 (67 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.